Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBIT Margin (2016 - 2026)

Gyre Therapeutics has reported EBIT Margin over the past 15 years, most recently at 22.41% for Q4 2025.

  • Quarterly EBIT Margin fell 2480.0% to 22.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.6% through Dec 2025, down 1268.0% year-over-year, with the annual reading at 2.6% for FY2025, 1268.0% down from the prior year.
  • EBIT Margin was 22.41% for Q4 2025 at Gyre Therapeutics, down from 22.66% in the prior quarter.
  • Over five years, EBIT Margin peaked at 39.84% in Q3 2023 and troughed at 1851.51% in Q1 2022.
  • The 5-year median for EBIT Margin is 5.25% (2025), against an average of 403.68%.
  • Year-over-year, EBIT Margin crashed -149855bps in 2021 and then soared 187824bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 832.5% in 2021, then soared by 97bps to 22.13% in 2022, then plummeted by -1425bps to 337.53% in 2023, then soared by 101bps to 2.39% in 2024, then plummeted by -1039bps to 22.41% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBIT Margin are 22.41% (Q4 2025), 22.66% (Q3 2025), and 8.11% (Q2 2025).